Shire Biologics Facility

(2:22)

Shire goes Viro

(2:41)

Shire Biologics Facility

(2:22)

Shire is a Rare Disease Company

(3:46)

Customer Testimonial: Shire Pharmaceuticals

(1:47)

Interview with Flemming Ornskov of Shire at World Orphan Drug Congress USA 2013

(1:19)

Shire AG

(1:35)

Shire Pharmaceuticals is our share tip of the week - five reasons to invest

(1:39)

Shire (pharmaceutical company) | Wikipedia audio article

(12:39)

Shire's Orphan Drugs - Approved and In Development

(1:34)

Shire CEO Dr. Flemming Ornskoff

(2:27)

Japan's Takeda agrees to buy Shire for $62B | Money Talks

(6:25)

Shire's Russell Sees Adult Demand for ADHD Drugs Rising

(4:30)

Shire Pharmaceuticals

(3:6)

Japan's Takeda Pharmaceutical Weighs Bid for Shire

(2:45)

Changes to Come at Takeda After Shire Takeover

(1:46)

Ted Buckley, Head of Government Relations and Public Affairs, Shire Pharmaceuticals

(3:5)

A Conversation with Chris Sellin, Takeda (Formerly Shire)

(8:9)

Hartmann Wellhoefer Talks about Shire's Main Rare Disease Products

(8:41)